Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the full story at TechCrunch ↗
ImpactNotable 35/100
Why it mattersRule-based estimate: event keywords (+6); trust 7/10.
RegionsGlobal
Published1 d ago (Wed, 23 Sep 2026 19:31:28 GMT)
RetrievedWed, 23 Sep 2026 20:00:14 GMT via api
ClassifiedWed, 23 Sep 2026 20:00:35 GMT by heuristic
AuthorMarina Temkin